HIGHLIGHTS
- who: Conor J. Gallagher and collaborators from the Inc, Nashville, TN, USA Department of Dermatology and Skin Science, University of British Columbia and Cosmetic have published the article: Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials, in the Journal: Toxins 2023, 15, x FOR PEER REVIEW of 28/Nov/2022
- what: No neutralizing antibodies to daxibotulinumtoxinA were seen in this rigorous analysis from the large phase 3 program of DAXI, the novel BoNTA formulated with a PTDcontaining excipient RTP004, in the treatment of glabellar lines.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.